Veru Inc.

Veru Inc.

Veru Inc. originated as The Female Health Company, a manufacturer of female condoms, operating for decades as a niche consumer health business with steady, low-margin revenue. The firm rebranded to Veru in 2017 under Steiner's leadership, signaling an ambitious entry into prescription biopharmaceuticals. The legacy business was formally divested in 2022, completing the transformation into a clinical-stage oncology and metabolic pipeline company. Veru's pipeline concentrates on breast and prostate cancer therapies, anchored by its Phase 3 candidate enobosarm, an oral selective androgen receptor modulator (SARM). The company also advanced sabizabulin, a microtubule disruptor, through multiple indications, including COVID-19-related acute respiratory distress syndrome, which saw temporary FDA interest during the pandemic. Beyond oncology, Veru targets metabolic disorders, exploring treatments for weight loss-associated muscle wasting, a complementary angle to the booming GLP-1 drug class. The capital model relies entirely on public equity raises as a Nasdaq-listed entity, with no disclosed asset-management structure or family-office pool. Veru operates from Miami, Florida, with fewer than 100 professionals. As a publicly traded biotech valued below $2 billion, it reports financials that show no deployable assets under management — the firm burns cash on R&D rather than managing third-party capital. The balance sheet is the vehicle, not a fund. In February 2024, the company announced a 1-for-10 reverse stock split to maintain Nasdaq listing compliance, a defensive move reflecting the capital-constrained reality of late-stage biotech development without blockbuster revenue. The structural differentiator is the complete absence of a fund architecture — Veru is a slow-burn clinical pipeline operating inside a public corporate shell. Unlike family offices or venture arms that co-invest alongside other institutions, Veru's fate is binary: FDA approval or continued dilution. The governance sits squarely with Steiner, a urologist by training, who has helmed the strategic pivot from day one.